
Sign up to save your podcasts
Or


Dr Joyce O’Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, Dr Mark D Pegram from Stanford Cancer Institute in California, and Prof Peter Schmid from Barts Cancer Institute in London, United Kingdom, summarize currently available data guiding treatment decision-making for patients with low and ultralow HER2 expression and present cases from their practices.
CME information and select publications here.
By Dr. Neil Love4.9
5656 ratings
Dr Joyce O’Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, Dr Mark D Pegram from Stanford Cancer Institute in California, and Prof Peter Schmid from Barts Cancer Institute in London, United Kingdom, summarize currently available data guiding treatment decision-making for patients with low and ultralow HER2 expression and present cases from their practices.
CME information and select publications here.

135 Listeners

318 Listeners

494 Listeners

66 Listeners

31 Listeners

76 Listeners

14 Listeners

17 Listeners

12 Listeners

0 Listeners

115 Listeners

57 Listeners

3,338 Listeners

196 Listeners

44 Listeners

22 Listeners

364 Listeners

189 Listeners

43 Listeners

0 Listeners